Radioactive Iodine Therapy in Differentiated Thyroid Cancer: Summary of the Korean Thyroid Association Guidelines 2024 from Nuclear Medicine Perspective, Part-II

초록

Thyroid cancer, one of the most common endocrine tumors, generally has a favorable prognosis but remains a significantmedical and societal concern due to its high incidence. Early diagnosis and treatment of differentiated thyroid cancer (DTC)significantly affect long-term outcomes, requiring the selection and application of appropriate initial treatments to improveprognosis and quality of life. Recent advances in technology and health information systems have enhanced our understandingof the molecular genetics of thyroid cancer, facilitating the identification of aggressive subgroups and enabling theaccumulation of research on risk factors through big data. The Korean Thyroid Association (KTA) has revised the “KTAGuidelines on the Management of Differentiated Thyroid Cancers 2024” to incorporate these advances, which were developedby a multidisciplinary team and underwent extensive review and approval processes by various academic societies. This article summarizes the 2024 KTA guidelines for radioactive iodine (RAI) therapy in patients with DTC, written by theNuclear Medicine members of the KTA Guideline Committee, and covers RAI therapy as initial management of DTC andRAI therapy in advanced thyroid cancer.

키워드